| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Zhen Yang | |
| Wenting Xu | |||
| Nonghua Lu | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy | Q26798420 | ||
| Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial | Q26824777 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients | Q27852057 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. | Q27853081 | ||
| Cdks, cyclins and CKIs: roles beyond cell cycle regulation | Q28294632 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients | Q31152878 | ||
| EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation | Q33328407 | ||
| A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer | Q33387432 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer | Q33651388 | ||
| Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer | Q33796176 | ||
| Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536 | Q33810763 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials | Q33933669 | ||
| Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. | Q33990928 | ||
| Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo | Q34075366 | ||
| HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer | Q34104074 | ||
| Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. | Q34167172 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy | Q34455301 | ||
| Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas | Q34498746 | ||
| Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins. | Q34693039 | ||
| Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials | Q35061280 | ||
| Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma | Q35083852 | ||
| Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma | Q35609719 | ||
| BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A | Q35664516 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. | Q53376132 | ||
| A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. | Q54390371 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma | Q58614911 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction | Q84814758 | ||
| Gastric cancer epidemiology and risk factors | Q85369255 | ||
| Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer | Q86445750 | ||
| Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction | Q35753530 | ||
| Therapeutic strategies in epithelial ovarian cancer | Q35845484 | ||
| Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. | Q35927364 | ||
| Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer | Q36072056 | ||
| VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue | Q36577756 | ||
| Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial | Q36644664 | ||
| A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. | Q36745599 | ||
| Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy | Q36848774 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. | Q36941194 | ||
| Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). | Q37401491 | ||
| Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors | Q37468304 | ||
| Characteristics of gastric cancer in Asia | Q37724638 | ||
| Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. | Q37831541 | ||
| Clinical activity of mammalian target of rapamycin inhibitors in solid tumors | Q37871915 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Pertuzumab in gastrointestinal cancer | Q38653309 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells | Q39413378 | ||
| Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models | Q39519148 | ||
| Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts | Q39563719 | ||
| Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. | Q39736030 | ||
| Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. | Q40032261 | ||
| Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. | Q40715769 | ||
| Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial | Q41503961 | ||
| Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells | Q42423787 | ||
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). | Q43604675 | ||
| A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer | Q43830000 | ||
| Assessment of CD105, α-SMA and VEGF expression in gastric carcinomas | Q44019708 | ||
| FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study | Q44240338 | ||
| Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer | Q45091889 | ||
| Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer | Q45402955 | ||
| Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. | Q45776083 | ||
| Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer | Q46119167 | ||
| Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study | Q46691777 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| antineoplastic | Q2853144 | ||
| stomach neoplasm | Q4335552 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1 | |
| P577 | publication date | 2016-01-04 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | Molecular targeted therapy for the treatment of gastric cancer | |
| P478 | volume | 35 |
| Q64060021 | A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients |
| Q64955862 | A-kinase-interacting protein 1 facilitates growth and metastasis of gastric cancer cells via Slug-induced epithelial-mesenchymal transition. |
| Q90672870 | Anti-gastric cancer activity of 1,2,3-triazolo[4,5-d]pyrimidine hybrids (1,2,3-TPH): QSAR and molecular docking approaches |
| Q42269977 | Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model |
| Q52783141 | Basic Transcription Factor 3 Is Required for Proliferation and Epithelial-Mesenchymal Transition via Regulation of FOXM1 and JAK2/STAT3 Signaling in Gastric Cancer. |
| Q91815478 | Benzyl Isothiocyanate Induces Apoptosis via Reactive Oxygen Species-Initiated Mitochondrial Dysfunction and DR4 and DR5 Death Receptor Activation in Gastric Adenocarcinoma Cells |
| Q51102743 | CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways. |
| Q100945798 | ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma |
| Q52586720 | Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway. |
| Q98159102 | Effects of S-1 combined with palliative care on immune function and quality of life of patients with advanced stomach cancer |
| Q38699905 | Effects of salinomycin and 17‑AAG on proliferation of human gastric cancer cells in vitro |
| Q40225793 | Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. |
| Q33604781 | Establishment and Characterization of a Nude Mouse Model of Subcutaneously Implanted Tumors and Abdominal Metastasis in Gastric Cancer |
| Q37302281 | Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro |
| Q28067159 | From pathogenesis to clinical application: insights into exosomes as transfer vectors in cancer |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q41204446 | HOXC10 Promotes the Metastasis of Human Lung Adenocarcinoma and Indicates Poor Survival Outcome |
| Q38729414 | High expression of long non-coding RNA ATB indicates a poor prognosis and regulates cell proliferation and metastasis in non-small cell lung cancer |
| Q90650126 | Hsa_circ_0001649 restrains gastric carcinoma growth and metastasis by downregulation of miR-20a |
| Q89821434 | Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib |
| Q38736541 | JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo |
| Q47140260 | Krüppel-like factor 2 suppresses human gastric tumorigenesis through inhibiting PTEN/AKT signaling |
| Q89477386 | Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer |
| Q33788005 | Metadherin regulates actin cytoskeletal remodeling and enhances human gastric cancer metastasis via epithelial-mesenchymal transition |
| Q37640599 | MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression |
| Q26738548 | New advances in targeted gastric cancer treatment |
| Q33635033 | Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. |
| Q58720903 | Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer |
| Q88959338 | Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer |
| Q59142901 | Robust Nonnegative Matrix Factorization via Joint Graph Laplacian and Discriminative Information for Identifying Differentially Expressed Genes |
| Q91688483 | Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments |
| Q64080873 | Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients |
| Q38922319 | Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. |
| Q60045786 | TRIM37 promotes cell invasion and metastasis by regulating SIP1-mediated epithelial–mesenchymal transition in gastric cancer |
| Q30152777 | The role of IL-37 in cancer. |
| Q90637341 | Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism |
| Q89530028 | lncRNA ROR Promotes Gastric Cancer Drug Resistance |
| Q49515320 | miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy |
| Q89341719 | miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139 |
| Q58751038 | promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway |
Search more.